

## Case Report

# A case report of gastrointestinal stromal tumor of the duodenum

Danqiong Hu<sup>1\*</sup>, Yangri Duan<sup>1\*</sup>, Yonghua Chen<sup>2</sup>, Bingfeng Li<sup>3</sup>, Yechun Du<sup>1</sup>, Shuimei Shi<sup>4</sup>

Departments of <sup>1</sup>Gastroenterology, <sup>2</sup>Emergency, <sup>3</sup>General Surgery, <sup>4</sup>Internal Medicine-Cardiovascular, The Third People's Hospital of Yuhang District, Hangzhou 311100, Zhejiang, China. \*Equal contributors.

Received October 8, 2022; Accepted October 28, 2022; Epub November 15, 2022; Published November 30, 2022

**Abstract:** Introduction: Gastrointestinal stromal tumors (GISTs) rarely occur in the duodenum, and only a few cases have been reported. Its clinical manifestations are not specific, and the imaging examination results are not typical, so a preoperative diagnosis is difficult. Pathologic examinations and genetic testing after surgical resection are the main diagnostic methods. Here, a case of duodenal stromal tumor complicated by gastrointestinal perforation is reported. A 57-year-old man presented with paroxysmal abdominal pain and bloating for 7 days. Contrast-enhanced computed tomography of the abdomen revealed a large mass (10 cm in diameter) in the right upper abdomen, which was considered neoplastic. The mass was anterior and inferior to the head of the pancreas, and medial to the mesenteric vessels. The tumor surrounded the descending and horizontal parts of the duodenum, and it ruptured into the lumen of the descending duodenum. After the patient underwent tumor resection, we found a rupture of the descending duodenal opening. After that, duodenal fistula drainage, gastrostomy, jejunostomy, small intestinal adhesion release and abdominal irrigation drainage were performed. Immunohistochemical staining results were as follows: CD34 (-), desmin (-), S-100 (-), CD117 (9.7) (+), DoG-1 (+), SDHB (+), Ki-67 (+5%). Based on these results, the lesion was finally diagnosed as duodenal GIST. The patient underwent surgical resection without targeted therapy and recovered well. Discussion: Duodenal stromal tumors often present with gastrointestinal bleeding and other clinical symptoms, requiring urgent surgery. Complete resection of the tumor is an effective surgical method. Extended resection does not prolong survival. However, surgical treatment should be determined according to the size and location of the tumor and its relationship to the pancreas. This highly malignant duodenal stromal tumor was >10 cm, accompanied by gastrointestinal perforation and necrosis. Surgical resection was required while protecting the organ function.

**Keywords:** Duodenum, gastrointestinal stromal tumor, perforation, surgery

## Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, accounting for 1-3% of all gastrointestinal malignancies [1]. Duodenal stromal tumors are rare tumors among GISTs, accounting for 4-5% of GISTs [2]. Most of them develop in people over 40 years old, and there is no obvious sex difference [3]. It is primarily located in the descending and horizontal parts of the duodenum, adjacent to the liver, pancreas, and other important organs, so it has special characteristics for diagnosis and treatment. Duodenal stromal tumors are usually asymptomatic in their early stages and found incidentally. As the tumor continues to grow, there may be abdominal pain, blood in the

stool, abdominal mass, intestinal obstruction, and acute peritonitis caused by perforation [4].

KIT gene mutation is found in 75-80% of GISTs, and PDGFR $\alpha$  mutation is found in 10-15% of GISTs [5]. After these mutations, the anti-apoptotic mechanism is abolished, which promotes rapid growth of tumor cells. Computed tomography (CT) is still the first routine examination for GISTs. It can be used not only for diagnosis and differential diagnosis, but also for evaluation of efficacy of targeted drugs and detection of tumor recurrence and metastasis. The final diagnosis relies on pathology, immunohistochemistry and molecular testing.

Surgery remains the preferred and effective treatment for GISTs. It is usually necessary to




**Figure 1.** Image of abdominal computed tomography.

comprehensively consider the location, volume, and nature of the tumor, and the extent of invasion of surrounding tissues. The surgical principle of duodenal GISTs should be complete tumor resection to avoid tumor rupture and implantation metastasis [2, 6]. For duodenal GISTs in special locations requiring combined organ resection, if it is difficult to perform R0 resection, imatinib can be used for preoperative treatment [7]. Due to the relative rarity of duodenal GISTs, clinicians have little understanding about its clinical features, diagnosis, treatment and prognosis. In this study, we report a case of duodenal GIST with gastrointestinal perforation. Informed consent was signed by the patient.

### Case report


A 57-year-old man presented with 7 days of abdominal pain accompanied by anorexia, without nausea, vomiting or melena. The pain was intermittent. He had a history of neurofibroma and a history of mental retardation. He was a non-smoker with no alcohol history. Physical examination found pale palpebral conjunctivae, yellowish skin, abdominal bulge, mass in the right upper abdomen and abdominal pain. His routine blood examination showed leukocytes  $20.26 \times 10^9/L$ , neutrophil ratio 90.6%, hemoglobin 47 g/L and platelets  $528 \times 10^9/L$ . Abdominal CT scan suggested a soft tissue tumor with the presence of peritoneal ascites in the right upper abdomen. After admission to the Department of General Surgery, he underwent contrast-enhanced CT scan of the abdomen (**Figure 1**), and the scan image revealed a soft tissue mass (10.06 cm  $\times$  7.08 cm) with areas of necrosis in the right upper abdomen, suggesting a stromal tumor. The pancreatic



**Figure 2.** Tumor cell morphology (hematoxylin-eosin stain,  $\times 100$ ).

and the common bile ducts were dilated. The mass appeared to compress the descending part of the duodenum and the mesenteric vessels. An exploratory laparotomy and excision of the mass were performed. Intraoperatively, the abdomen and the pelvis were found with ascites. The mass (11.0 cm  $\times$  8.0 cm) was located posterior to the small intestinal mesenteric area in the right upper abdomen, with a brittle and hard texture. The surface of the mass broke and exuded into the abdominal cavity. The mass was located anteriorly below the head of the pancreas, medial to the vessels of the root of the mesentery. The tumor encircled the descending and horizontal parts of the duodenum, and in the region of the descending duodenum, tumor ruptured into the lumen. After resection of the tumor, further exploration revealed a ruptured opening in the descending duodenum of about 2.0 cm with bile and digestive fluid. With consent from his family, a right upper abdominal retroperitoneal tumor resection + duodenal fistula repair with tube drainage + gastrostomy + jejunostomy + small intestine adhesion release + abdominal flushing and drainage were performed, during which 2 units of blood were transfused intraoperatively. In terms of postoperative pathology, the tumor cell morphology is shown in **Figure 2**. Immunohistochemical results (**Figure 3**) were as follows, CD34 (-), desmin (-), S-100 (-), CD117 (9.7) (+), DOG-1 (+), SDHB (+), Ki-67 (+5%). The morphology of retroperitoneal mass combined with immunohistochemistry was consistent with gastrointestinal mesenchymal tumor of high risk type. Postoperatively, he recovered well without early significant complications and

## Gastrointestinal stromal tumor of the Duodenum



**Figure 3.** Immunohistochemical results.

did not need targeted therapy, and the hemoglobin gradually increased. The patient was discharged 10 days after the operation, and 4 months after the operation, he was well with no evidence of tumor recurrence.

### Discussion

The global incidence of gastrointestinal stromal tumor (GIST) is about 1-1.5 per 100,000 [8]. There are about 20,000-30,000 newly diagnosed patients in China each year, and more than 100,000 patients are receiving treatment [8, 9]. GISTs can involve the entire gastrointestinal tract, of which the stomach accounts for 60%, small intestine 25%, rectum 5%, and colon, esophagus, omentum, mesentery, and retroperitoneum less than 5% [9]. The treatment of GIST mainly relies on surgery and molecular-targeted drugs.

GISTs have the ability for malignant transformation, and the risk is closely related to tumor

size, location, and mitotic figures. GISTs are initially surrounded by normal tissues such as mucosa, serosa and muscularis propria, forming a protective biological barrier that avoids injury [10].

We retrieved relevant case reports in the PubMed database using gastrointestinal stromal tumor and duodenum as keywords and obtained 19 samples (**Table 1**). The analysis of 20 cases (19 cases retrieved plus our case) showed that duodenal GIST was more common in people over 50 years old. The patients were aged between 21 and 84 years, with 7 women and 13 men. Tumor size varied from 1.6 to 15 cm, with an average of 6.2 cm. The majority of the (11) tumors were located in the second part of the duodenum, and a small number of patients had tumor located in the first, third and fourth parts.

The manifestation of symptoms is mainly related to growth site, size, relationship to the gas-

## Gastrointestinal stromal tumor of the Duodenum

**Table 1.** Literature review

Study	Age	Sex	Size	Duodenal portion location	Surgical treatment	Symptoms and sign at admission
Cavallini 2005 [14]	66	M	3.5	Second	Local resection	Anemia, melena
Mohiuddin 2007 [15]	56	M	10.0	Second	Local resection	Anemia, melena
Hecker 2010 [19]	58	M	15.0	Second	PD	Abdominal pain, anemia, weight loss
Mokhtare 2013 [35]	24	M	3.0	Third and fourth	Local resection	Acute upper gastrointestinal bleeding
Acar 2013 [21]	65	F	3.2	Third	Local resection	Abdominal pain
Kobayashi 2014 [36]	36	M	2.2	Second	PD	Loss of consciousness
Kumar 2015 [22]	55	F	15.0	Third	PD	Abdominal pain
Turculeț 2016 [13]	48	M	7.0	Second and third	PD	Melena, asthenia and dizziness
Jung 2017 [16]	72	M	6.5	NM	Local resection	Melena
Santos 2020 [37]	75	M	10.0	Third and fourth	PD	Asymptomatic
Sasaki 2020 [20]	68	M	2.4	Second	PD	Abdominal pain
Pyuza 2021 [38]	40	M	5.0	Third and fourth	Local resection	Asymptomatic
Inoue 2022 [4]	44	F	3.0	First	PD	Anemia
Ito 2022 [12]	84	M	3.5	Second	Local resection	Melena
	58	M	3.0	Second	Local resection	Anemia
	57	F	9.2	Second	Local resection	Ischemic colitis
Skhiri 2022 [17]	21	F	5.2	Second	PD	Abdominal pain, melena
Harhar 2022 [23]	54	F	6.3	Fourth	Local resection	Abdominal pain
Mita 2022 [18]	57	F	1.6	Second	Local resection	Melena

Note: PD indicatespancreaticoduodenectomy.

gastrointestinal wall, and whether the tumor is ruptured [11]. As the tumor grows, a pseudocapsule can be formed by compression of normal tissue, and necrosis or spontaneous rupture of the tumor can occur to a certain extent, leading to gastrointestinal perforation, hemorrhage and peritonitis [12]. Common symptoms are gastrointestinal bleeding, abdominal pain, melena, and abdominal mass. Early cases can be asymptomatic. Studies [12-18] have reported symptoms in 70,000 patients with melena. Five cases with anemia were reported [4, 12, 14, 15, 19]. Six patients (five cases from the literature plus our case) developed abdominal pain [17, 19-23].

Because of the atypical clinical manifestations of duodenal GIST, multiple examinations should be combined for diagnosis. GIST diagnosis mainly relies on CT, MRI, PET-CT, ultrasound endoscopy, and other related examinations. Endoscopic gastric GIST mainly shows submucosal local elevation, and is mostly spherical or hemispherical, with a smooth mucosal surface [24-26]. Large lesions may be accompanied by ulceration, necrosis, or bleeding [13]. Contrast-enhanced CT is the preferred imaging method for GIST, and can identify tumor location, size, growth mode, adjacent peripheral

organs, blood supply, and distant metastasis. Low grade GIST is characterized by uniform density, sharp edge, rarely invasion of adjacent organs, and calcification [27]. When the grade of malignancy is high, the tumor has unclear boundaries, and can be adherent to adjacent organs, frequently with central necrosis, bleeding, cystic degeneration, and rare calcification [27, 28]. Liver metastases on enhanced CT can be further evaluated by MRI. Our case was not evaluated by MRI. In the 20 retrieved studies, 19 cases underwent tissue examination after surgical resection to confirm GIST. One case was diagnosed by endoscopic biopsy.

The final diagnosis relies on histopathologic and immunohistochemical examinations. Immunohistochemical routine detection includes CD117, DOG-1, CD34, S-100, SDHB and KI-67. The histopathologic results of this study were: CD34 (-), desmin (-), S-100 (-), CD117 (9.7) (+), DOG-1 (+), SDHB (+), and Ki-67 (+5%). CD117 is the protein product of the proto-oncogene c-kit, which has a positive expression rate of 94-98% in GISTs with good sensitivity and specificity. DOG-1 is the protein product of the proto-oncogene platelet-derived growth factor receptor  $\alpha$  (PDGFRA), which has a positive expression rate of 94-98% in GISTs [29]. CD117 and

## Gastrointestinal stromal tumor of the Duodenum

DOG-1 are important immunohistochemical markers for the diagnosis of GIST. Ki-67 is a marker of cell proliferation in a variety of malignancies, associated with poor pathologic features and aggressive behavior, and is prognostically important [30]. However, not all immunohistochemical markers are always positive. Harhar et al. [23] found that the tumor cells of a duodenal GIST did not express CD117, but expressed DOG-1 due to a PDGFRA mutation. Therefore, some cases that cannot be diagnosed by immunohistochemical examination can be further identified by mutational testing.

Currently, surgery is the treatment of choice for GIST, and the main surgical options are minimally invasive endoscopic surgery of the gastrointestinal tract, minimally invasive laparoscopic surgery, combined biomicroscopic surgery and traditional open surgery. Surgical resection is considered the main method to treat duodenal GIST. Pancreaticoduodenectomy and local resection (12) were performed in all reported cases. The surgical method is chosen mainly based on the size and location of the GIST. National Comprehensive Cancer Network Clinical Practice Guidelines for GISTs (Version 2. 2022) [27] suggested that surgical resection should be performed on tumors, with negative histological margins. Laparoscopic surgery is safe and feasible for GIST ranging from 5 to 10 cm in diameter and does not increase perioperative complications [27]. The Chinese Society of Clinical Oncology [28] recommends that tumors  $\leq 2$  cm can be assessed annually with endoscopic ultrasonography. R0 resection should be performed for tumors  $> 2$  cm or with undesirable biologic behavior. The duodenal GIST case in this study was located in the second and third parts of the duodenum, and in the right upper retroperitoneum, with a diameter of 10 cm. Therefore, an R0 resection of the right superior retroperitoneal tumor was performed. The patient was well without tumor recurrence, and follow-up is ongoing. Marcella et al. [31] concluded that endoscopic submucosal dissection and laparoscopic approach have the same resection rate for GISTs with a diameter between  $\leq 2$  cm and 2-5 cm. However, Lei et al. [32] suggested that laparoscopic surgery may be more appropriate for gastric GISTs between 2 and 5 cm in diameter. The duodenum is the structure with the

most complex adjacent anatomic relationship among the abdominal organs. In order to protect organ function, local surgery to remove the tumor should be attempted. On the basis of ensuring the complete resection of the tumor, extensive operation such as pancreaticoduodenectomy should be minimized [28].

For a GIST that cannot be resected or has metastases, targeted drug therapy is the main approach. However, if there is no progress in treatment, or if there is bleeding or obstruction, surgical resection may be required. Tyrosine kinase inhibitors are available for patients with unresectable, metastatic or recurrent GIST [16, 33]. Imatinib, sunitinib and regorafenib are first-, second- and third-line therapies for patients with GIST, respectively [28].

Malignant GISTs have a high recurrence and metastasis rate and an extremely poor prognosis. The 5-year survival rate after surgery for gastrointestinal mesenchymal tumors was found to be 30.5-73.2% [7, 34]. As screening equipment develops rapidly, the positive diagnosis rate of GISTs has increased significantly, and the clinical awareness of GIST is growing. Because of its aggressiveness, early detection and treatment are of value for patients.

### Disclosure of conflict of interest

None.

**Address correspondence to:** Yangri Duan, Department of Gastroenterology, The Third People's Hospital of Yuhang District, Hangzhou 311100, Zhejiang, China. E-mail: duanyangri@163.com

### References

- [1] Fan X, Han H, Sun Z, Zhang L, Chen G, Mzee SAS, Yang H and Chen J. Prognostic value of bleeding in gastrointestinal stromal tumors: a meta-analysis. *Technol Cancer Res Treat* 2021; 20: 15330338211034259.
- [2] Buchs NC, Bucher P, Gervaz P, Ostermann S, Pugin F and Morel P. Segmental duodenectomy for gastrointestinal stromal tumor of the duodenum. *World J Gastroenterol* 2010; 16: 2788-2792.
- [3] Yin Z, Gao J, Liu W, Huang C, Shuai X, Wang G, Tao K and Zhang P. Clinicopathological and prognostic analysis of primary gastrointestinal stromal tumor presenting with gastrointestinal bleeding: a 10-year retrospective study. *J Gastrointest Surg* 2017; 21: 792-800.

## Gastrointestinal stromal tumor of the Duodenum

- [4] Inoue M, Ohmori I, Watanabe A, Kajikawa R, Kajiwara R, Sawada H, Miyamoto K, Ikeda M, Toyota K, Sadamoto S and Takahashi T. A duodenal gastrointestinal stromal tumor mimicking a pancreatic neuroendocrine tumor: a case report. *J Med Case Rep* 2022; 16: 308.
- [5] Mas L and Bachet JB. [Advanced GIST: Which treatments in 2022?]. *Bull Cancer* 2022; 109: 1082-1087.
- [6] Popivanov G, Tabakov M, Mantese G, Cirocchi R, Piccinini I, D'Andrea V, Covarelli P, Boselli C, Barberini F, Tabola R, Pietro U and Cavaliere D. Surgical treatment of gastrointestinal stromal tumors of the duodenum: a literature review. *Transl Gastroenterol Hepatol* 2018; 3: 71.
- [7] Tang L, Sui Y, Zhong Z, Damen FC, Li J, Shen L, Sun Y and Zhou XJ. Non-Gaussian diffusion imaging with a fractional order calculus model to predict response of gastrointestinal stromal tumor to second-line sunitinib therapy. *Magn Reson Med* 2018; 79: 1399-1406.
- [8] Lin C, Zhang ZL and Wang L. Update on diagnosis and treatment of gastrointestinal stromal tumors. *Cancer Research on Prevention and Treatment* 2022; 49: 1-4.
- [9] Li J and Shen L. The current status of and prospects in research regarding gastrointestinal stromal tumors in China. *Cancer* 2020; 126 Suppl 9: 2048-2053.
- [10] Zhou L, Liao Y, Wu J, Yang J, Zhang H, Wang X and Sun S. Small bowel gastrointestinal stromal tumor: a retrospective study of 32 cases at a single center and review of the literature. *Ther Clin Risk Manag* 2018; 14: 1467-1481.
- [11] Yeh CH, Pan KT, Chu SY, Chen CM, Hsu MY, Hung CF and Tseng JH. Safety and efficacy of image-guided percutaneous biopsies in the diagnosis of gastrointestinal stromal tumors. *Clin Imaging* 2012; 36: 19-23.
- [12] Ito T, Kushida T, Sakurada M, Tanaka K, Sato K and Maekawa H. Complete wedge resection for duodenal gastrointestinal stromal tumour: a case series of three patients. *Int J Surg Case Rep* 2022; 90: 106674.
- [13] Turculeț C, Ene D, Georgescu TF, Ciucă E, Vlădășcău A, Iordache F and Beuran M. A rare case of upper digestive hemorrhage due to bleeding duodenal tumor. *Chirurgia (Bucur)* 2016; 111: 505-508.
- [14] Cavallini M, Cecera A, Ciardi A, Caterino S and Ziparo V. Small periampullary duodenal gastrointestinal stromal tumor treated by local excision: report of a case. *Tumori* 2005; 91: 264-266.
- [15] Mohiuddin K, Nizami S, Munir A, Memon B and Memon MA. Metastatic duodenal GIST: role of surgery combined with imatinib mesylate. *Int Semin Surg Oncol* 2007; 4: 9.
- [16] Jung M, Park SH, Jeon YK, Won JK, Yang HK and Kim WH. Gastrointestinal stromal tumor of unusual phenotype after imatinib treatment: a case report and diagnostic utility of ETV1 mRNA in situ hybridization. *Medicine (Baltimore)* 2017; 96: e9031.
- [17] Skhiri W, Saad J, Mazhoud I, Maatouk M, Chaouch A and Salem AB. Gastrointestinal stromal tumor of the ampulla of Vater: a case report and literature review. *Int J Surg Case Rep* 2022; 99: 107598.
- [18] Mita J, Tada K, Kuboyama Y, Hiroshige S, Nakamura S, Takahashi J, Sakata K, Mizuuchi H, Oba T, Yoshizumi F, Iwaki K, Takeuchi H, Kajiyama K and Fukuzawa K. Liver metastases 2 years after resection of a very-low-risk duodenal gastrointestinal stromal tumor: a case report. *Surg Case Rep* 2022; 8: 195.
- [19] Hecker A, Hecker B, Bassaly B, Hirschburger M, Schwandner T, Janssen H and Padberg W. Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review. *World J Surg Oncol* 2010; 8: 47.
- [20] Sasaki S, Takami Y, Wada Y, Ryu T, Imamura H, Ureshino H, Fujiwara M and Saito H. Glomus tumor of the duodenum: a rare case report. *Surg Case Rep* 2020; 6: 305.
- [21] Acar F, Sahin M, Ugras S and Calisir A. A gastrointestinal stromal tumor of the third portion of the duodenum treated by wedge resection: a case report. *World J Gastrointest Surg* 2013; 5: 332-336.
- [22] Kumar A, Jakhmola CK, Chauhan SS and Singh A. Atypical presentation of gastrointestinal stromal tumor masquerading as a large duodenal cyst: a case report. *Int J Surg Case Rep* 2015; 9: 123-126.
- [23] Harhar M, Harouachi A, Akouh N, Atmani A, Aabdi H, Bouhout T, Bennani A, Serji B and El Harroudi T. Gastrointestinal stromal tumor in the fourth portion of the duodenum does not express the CD117: a case report. *Ann Med Surg (Lond)* 2022; 77: 103560.
- [24] Hayashi K, Kamimura K, Hosaka K, Ikarashi S, Kohisa J, Takahashi K, Tominaga K, Mizuno K, Hashimoto S, Yokoyama J, Yamagiwa S, Takizawa K, Wakai T, Umezu H and Terai S. Endoscopic ultrasound-guided fine-needle aspiration for diagnosing a rare extraluminal duodenal gastrointestinal stromal tumor. *World J Gastrointest Endosc* 2017; 9: 583-589.
- [25] Mahawongkajit P, Techagumpuch A and Suthiwartnarueput W. Non-exposed endoscopic wall-inversion surgery for a gastrointestinal stromal tumor of the stomach: a case report. *Oncol Lett* 2017; 14: 4746-4750.
- [26] Harris PS, Romano J, Russ KB, Shoreibah MG and Baig KRKK. Gastrointestinal stromal tumor: GIST another duodenal ulcer. *Ochsner J* 2020; 20: 236-238.

## Gastrointestinal stromal tumor of the Duodenum

- [27] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastrointestinal stromal tumors (GISTs), version 2. 2022.
- [28] Oncology GwCoCSoc. Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of gastrointestinal stromal tumors 2022. Beijing: 2022.
- [29] Ríos-Moreno MJ, Jaramillo S, Pereira Gallardo S, Vallejo A, Mora M, García-Escudero A, Amérgo J and González-Cámpora R. Gastrointestinal stromal tumors (GISTs): CD117, DOG-1 and PKC $\theta$  expression. Is there any advantage in using several markers? *Pathol Res Pract* 2012; 208: 74-81.
- [30] Sahin S, Ekinci O, Seckin S and Dursun A. Proliferation markers RacGAP1 and Ki-67 in gastrointestinal stromal tumors by immunohistochemistry with respect to clinicopathological features and different risk stratification systems. *Int J Clin Exp Pathol* 2017; 10: 11723-11736.
- [31] Marcella C, Shi RH and Sarwar S. Clinical overview of GIST and its latest management by endoscopic resection in Upper GI: a literature review. *Gastroenterol Res Pract* 2018; 2018: 6864256.
- [32] Lei T, Tan F, Liu H, Ouyang M, Zhou H, Liu P, Zhao X and Li B. Endoscopic or surgical resection for patients with 2-5 cm gastric gastrointestinal stromal tumors: a single-center 12-year experience from China. *Cancer Manag Res* 2020; 12: 7659-7670.
- [33] Wozniak A, Gebreyohannes YK, Debiec-Rychter M and Schöffski P. New targets and therapies for gastrointestinal stromal tumors. *Expert Rev Anticancer Ther* 2017; 17: 1117-1129.
- [34] Hawkins AT, Wells KO, Krishnamurthy DM, Hunt SR, Mutch MG, Glasgow SC, Wise PE and Silveira ML. Preoperative chemotherapy and survival for large anorectal gastrointestinal stromal tumors: a national analysis of 333 cases. *Ann Surg Oncol* 2017; 24: 1195-1201.
- [35] Mokhtare M, Taghvaei T and Tirgar Fakheri H. Acute bleeding in duodenal gastrointestinal stromal tumor. *Middle East J Dig Dis* 2013; 5: 47-51.
- [36] Kobayashi M, Hirata N, Nakaji S, Shiratori T, Fujii H and Ishii E. Gastrointestinal stromal tumor of the ampulla of Vater: a case report. *World J Gastroenterol* 2014; 20: 4817-4821.
- [37] Santos AJ, Tojal A, Duarte L, Marques C, Pinheiro LF and Casimiro C. Asymptomatic large duodenal GIST-an incidental finding in abdominopelvic ultrasonography: a case report. *Int J Surg Case Rep* 2020; 76: 301-304.
- [38] Pyuza JJ, Shao ER, Bosco K, Lodhia J and Mremi A. An incidental finding of duodenal GIST in a patient with penetrating abdominal trauma: a case report. *Int J Surg Case Rep* 2021; 85: 106263.